Welcome to our dedicated page for Waterdrop news (Ticker: WDH), a resource for investors and traders seeking the latest updates and insights on Waterdrop stock.
Waterdrop Inc. (NYSE: WDH) is a technology platform dedicated to insurance and healthcare services, and its news flow centers on business performance, AI deployment, and social impact. Regular announcements include unaudited quarterly financial results, where the company reports net operating revenue, net profit attributable to ordinary shareholders, and segment performance across insurance, crowdfunding, and digital clinical trial solutions.
News about Waterdrop’s insurance business often highlights insurance-related income, first-year premiums generated through its insurance marketplace, and the contribution of technical service income. Disclosures describe how AI tools such as the AI Medical Insurance Expert, KEYI.AI underwriting assistant, and AI Customer Service Agent are used to improve underwriting efficiency, handle customer inquiries, and support sales and service processes.
Updates on Waterdrop Medical Crowdfunding typically provide cumulative figures for donors, total donations, and patients supported, alongside descriptions of enhanced risk control frameworks, anti-fraud analytics, and donor evaluation systems. The company also releases information on its digital clinical trial solution and E-Find Platform, including patient enrollment numbers, the number of clinical trial programs served, and collaborations with pharmaceutical and contract research organizations.
Investors following WDH news will also see announcements about share repurchase programs, cash dividends, and conference call schedules for financial results. In addition, Waterdrop has reported recognition such as inclusion of its “Waterdrop: AI-Powered Insurance and Healthcare” case in the Harvard Business School Case Collection, underscoring external interest in its AI-powered insurance and healthcare model. For users tracking WDH, this news page aggregates these financial, operational, and corporate updates in one place.
Waterdrop (NYSE: WDH) reported strong Q4 and full‑year 2025 results: Q4 net operating revenue RMB1,411.2M (+105.5% YoY) and Q4 net profit attributable to shareholders RMB162.1M (+62.7% YoY). For 2025, revenue was RMB3,977.8M (+43.5% YoY) and net profit RMB568.9M.
The company held RMB3,249.0M cash at year-end, repurchased ~60.7M ADS by Feb 2026, and approved a ~US$10.8M cash dividend. Insurance operating profit was RMB644.9M; medical crowdfunding raised RMB72.3B for 3.68M patients. E-Find enrolled 14,555 patients into 1,611 trials.
Waterdrop (NYSE: WDH) reported strong fourth-quarter and full-year 2025 results and declared a cash dividend. Q4 net operating revenue rose 105.5% YoY to RMB1,411.2 million; Q4 net profit attributable to ordinary shareholders was RMB162.1 million, up 62.7% YoY. The company announced cumulative repurchases of ~60.7 million ADSs (~US$118.1 million) and a board‑approved cash dividend of ~US$10.8 million.
Management highlighted AI deployment across insurance, fraud controls for medical crowdfunding, and a patented intelligent drug‑patient matching technology supporting digital clinical trial growth.
Waterdrop (NYSE: WDH) will report unaudited fourth quarter and fiscal year 2025 results before U.S. markets open on March 25, 2026. Management will host an earnings conference call the same day at 8:00 AM ET (8:00 PM Beijing/Hong Kong).
Telephone dial-in numbers, interpretation lines, replay access through April 1, 2026, and a live/archived webcast on the company's investor relations site are provided for investors.
Waterdrop (NYSE: WDH) reported third-quarter 2025 unaudited results for the period ended Sept 30, 2025: net operating revenue RMB 974.9 million (+38.4% YoY) and net profit attributable to ordinary shareholders RMB 158.5 million (+60.1% YoY), marking the fifteenth consecutive profitable quarter.
Operating expenses fell to 39.6% of revenue, down 8.3 percentage points YoY. Since 2021, the company repurchased ~58.1 million ADSs through Nov 30, 2025. Insurance revenue grew to RMB 869.7 million (+44.8% YoY) with insurance operating profit RMB 176.4 million (+44% YoY). Medical crowdfunding raised RMB 71.2 billion for 3.61 million patients cumulatively.
Waterdrop (NYSE: WDH) reported unaudited Q3 2025 results on Dec 3, 2025: net operating revenue RMB974.9M (+38.4% YoY) and insurance-related income RMB869.7M (+44.8% YoY). Operating profit rose to RMB113.8M (+329.8% YoY) and net profit attributable to shareholders was RMB158.5M (+60.1% YoY). Cash position stood at RMB3,510.0M as of Sep 30, 2025. E-Find enrolled 13,282 patients cumulatively; medical crowdfunding facilitated RMB71.2B donated to 3.61M patients. Company repurchased ~58.1M ADSs for ~$113.4M through Nov 30, 2025.
Waterdrop (NYSE: WDH) won the Global Best Case Brands Award at the 3rd International Conference on Management Change and Sustainable Development on Dec 2, 2025, recognized from 100+ nominees for contributions to inclusive protection and case-based research.
The company highlights its AI and product milestones: ~RMB 300 million annual tech R&D since 2019, GuardianShuishou LLM filings and >100 AI patents, 214 pre-existing-condition insurance offerings in 2025, and Waterdrop Medical Crowdfunding which raised ~RMB 70 billion for 3.54 million patients as of Jun 2025.
Waterdrop (NYSE: WDH) will report its unaudited financial results for the third quarter ended September 30, 2025 before U.S. markets open on December 3, 2025. Management will hold an earnings conference call on December 3, 2025 at 7:00 AM ET (8:00 PM Beijing/Hong Kong Time) to discuss results.
Dial-in numbers are provided for international, U.S., Hong Kong and mainland China participants, with separate Chinese and English interpretation lines (English is listen-only). Telephone replays will be available through December 10, 2025. A live and archived webcast will be available on the company investor relations site at http://ir.waterdrop-inc.com/.
Waterdrop Inc. (NYSE:WDH) has released its 2024 ESG Report, highlighting significant achievements in technology innovation and social impact. The company maintained its A-level ESG rating while expanding its AI capabilities with over 100 AI-related patents and investing RMB 217 million in R&D.
Key achievements include the development of "Waterdrop Guardian" LLM, the launch of 174 inclusive insurance products, and the expansion of medical crowdfunding platform which has raised RMB 67.5 billion from 470 million contributors. The company has established 167 rural medical clinics serving over 500,000 beneficiaries and reduced its greenhouse gas emissions by 33.32% year-over-year.
Waterdrop Inc. (NYSE: WDH) reported strong Q2 2025 financial results, with net operating revenue reaching RMB 838.0 million, up 23.9% year-over-year. The company's net profit surged 58.7% to RMB 140.2 million, marking its 14th consecutive profitable quarter.
The insurance business showed exceptional performance with first-year premiums increasing 80.2% to RMB 3,204.3 million. Operating profit from insurance reached RMB 170.9 million, up 39% YOY. The company enhanced its product portfolio with innovative offerings, including the industry's first Million Medical Insurance policy with no health declaration requirement.
The board approved an enhanced cash dividend of US$10.9 million, a 50% increase over the previous dividend. The company's AI initiatives, including 'KEYI.AI' and Waterdrop Guardian, have significantly improved operational efficiency and user experience.
Waterdrop Inc. (NYSE: WDH) reported strong Q2 2025 financial results, with net profit reaching RMB140.2 million (US$19.6 million), up 58.7% year-over-year. The company's insurance business showed exceptional growth with first-year premiums (FYP) of RMB3,204.3 million, increasing 80.2% year-over-year.
Key highlights include: net operating revenue of RMB838.0 million (up 23.9% YoY), significant AI integration improvements, and expansion of the E-Find Platform to 198 pharmaceutical partnerships. The Board approved an enhanced cash dividend of US$10.9 million (50% increase) and authorized a fifth annual share repurchase program of up to US$50 million.
The company completed the Shenlanbao acquisition and enhanced its medical crowdfunding platform with advanced AI capabilities, now covering 480 million donors and facilitating RMB70.0 billion in donations to 3.54 million patients.